Silence Therapeutics plc
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Iain Gladstone Ross
- Full Time Employees
- 116
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 72 Hammersmith Road London United Kingdom W14 8TH
- IPO Date
- Sep 8, 2020
- CIK
- 0001479615
- Website
- silence-therapeutics.com
- Similar Companies
- Business
- Silence Therapeutics plc (Nasdaq: SLN), founded in 1994 and headquartered in Hammersmith, London, with additional offices in Hoboken, New Jersey, USA, and Berlin, Germany, develops proprietary short interfering RNA (siRNA) therapeutics utilizing its mRNAi GOLD™ platform to silence disease-causing genes in the liver for the treatment of rare and cardiovascular diseases. The company advances a wholly owned clinical pipeline including divesiran (SLN124), an siRNA targeting TMPRSS6 for hematological disorders such as beta-thalassemia and myelodysplastic syndromes; zerlasiran (formerly SLN360), an siRNA designed to reduce elevated lipoprotein(a) levels associated with cardiovascular risk, which demonstrated up to 99% reduction in Phase 1 studies lasting 90 days post-dosing; and other candidates like SLN-312, SLN-548 targeting rare diseases. It also licenses siRNA product candidates through partnerships, notably a collaboration with AstraZeneca featuring an ongoing Phase 1 study of SLN312 in an undisclosed indication, alongside prior agreements with Mallinckrodt Pharmaceuticals and Hansoh Pharma. Recent developments encompass pipeline progression with positive clinical data for zerlasiran reported in November 2023, quarterly financial updates through 2025 showing cash reserves exceeding $114 million to support operations into 2028, and strategic focus on high-unmet-need areas in hematology, cardiovascular disease, and rare disorders. Silence Therapeutics operates globally, partnering with pharmaceutical companies to expand its RNAi technology applications across therapeutic areas.
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
Silence Therapeutics to Participate in Jefferies Global Healthcare Conference
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Recommendation of “Moderate Buy” by Brokerages
Silence Therapeutics (NASDAQ:SLN) versus Avalo Therapeutics (NASDAQ:AVTX) Head-To-Head Comparison
Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of “Hold” from Brokerages
Silence Therapeutics Announces Leadership Changes
Silence Therapeutics: Divesiran Targets High-Burden PV
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Tonix Pharmaceuticals (NASDAQ:TNXP) versus Silence Therapeutics (NASDAQ:SLN) Critical Survey
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera